REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharma...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 16, 2024

transcosmos enhances ESG initiatives in South Korea, creates a playground for kids • DICK’S Sporting Goods & SidelineSwap Expand Resale Partnership in 2024 • Alcohol Justice to Participate in 23rd Annual UCLA Kaiser Permanente Equity Symposium • Torani Teams Up with Armstead Academic Project to Host “Career Camp,” Unlocking Educational & Career Pathways fo • Quilt Raises $33M to Launch the Smartest Way to Heat and Cool Your Home • Finastra integrates AI ESG scoring into trade and supply chain finance offering with TradeSun • The National Council's official statement on the BOP announcement to close FCI Dublin • Uptime Institute Launches Uptime Institute Sustainability Assessment for Digital Infrastructure • Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2% • Unveiling the Serenity of St. Gertrude Cemetery: A Not-to-Be-Missed Open House Event • WORLD VOICE DAY: Explorance Encourages People Around the World to Speak out about the Challenges they Face in Higher Education o • ELFBAR zeros in on vape recyclability in continuous dedication • Groundbreaking "At 25:00, in Akasaka" Marks First International Boys' Love Co-Production by TV Tokyo and GagaOOLala • Forbright Bank Healthcare Team Closes Three Deals to Kick Off 2024 • Monroe Capital Supports Leeds Equity Partners’ TouchMath • Him For Her Expands Board of Directors to Support Mission, Growth • Slone Partners Places Chris Raanes as CEO at Magnetic Insight • U.S. News Announces 2024 Best Senior Living Ratings • Canada's delegation to UNPFII advocates for the enhanced participation of Indigenous Peoples, including the unique and diverse p • Vena Closes FY24 With Record-Setting Q4, Customer Growth, Product Innovation and Industry Recognition

REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and En

NEW YORK , May 27 /Businesswire/ - Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf of Reata stockholders. Our investigation concerns whether Reata has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023. Among other items, Reata announced its decision to discontinue studies for its kidney disease candidate bardoxolone, which the Company had previously advanced as one of its lead assets in partnership with Blackstone Life Sciences and Kyoma Kirin.

On this news, Reata's stock price fell $14.99 per share or 14.23%, to close at $90.38 per share on May 10, 2023.

If you purchased or otherwise acquired Reata shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.